The board of directors of CSPC Pharmaceutical Group Limited announced that the Palbociclib Tablets developed by the Group, has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs. Palbociclib is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor that reduces cell proliferation in estrogen receptor (ER)-positive breast cancer cell lines by arresting cell progression from the G1 phase to the S phase. The Product is indicated for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer, and is used in combination with an aromatase inhibitor as initial endocrine therapy for postmenopausal women.

Compared to palbociclib capsules, the Product does not need to be taken with food and can eliminate drug interactions with proton pump inhibitors. The approval of the Product will further enrich the Group's oncology product portfolio.